Microbiome: The New Genetics?
Super Session 2
The human microbiome is considered a counterpart to the human genome, with the number of genes in our microbiome outnumbering the genes in our genome by 100 to 1. The microbiome is a set of highly interactive species which is heavily impacted by its surrounding environment and whose balance is vital to human health.
Today, gut microbiome is at the leading edge of scientific research across more than 170 countries. In this session, “Microbiome: the New Genetics?”, hosted by the Greater Copenhagen Microbiome Signature Project, we will hear from some of the world’s leaders on the current developments within microbiome research, such as host-microbe interactions and their implications on disease progression and treatment, where opportunities and challenges exist in translating proof-of-concept studies in animal models to clinical trials, and how research can transition from academia to industry to result in improved therapies and better therapeutic outcomes for patients. The discussions will further shed light on how the Nordics can play a key role in moving the field forward.
Moderator(s): Dr. Eric De La Fortelle - Venture Partner , Seventure Partners
Dr. Eric De La Fortelle - Venture Partner , Seventure Partners Dr. Paul Ross - Director, APC Microbiome Ireland Ms. Sarah Lidé - Senior Strategy & Project Manager, Medicon Valley Alliance Dr. Gianfranco Grompone - Chief Scientific Officer, BioGaia Ms. Sarah Lidé - Senior Strategy & Project Manager, Medicon Valley Alliance Dr. Paul Ross - Director, APC Microbiome Ireland Dr. Mirjam Mol-Arts - Chief Science and Medical Officer, Ferring Pharmaceuticals Dr. Henrik Bjørn Nielsen - Chief Scientific Officer, Clinical Microbiomics